F&P Healthcare lifts forecast, expands Mexico plant

Last updated 09:03 18/02/2014
FPH 9.500 0.05 0.53%
FPH

Click for a detailed chart

Relevant offers

Industries

Construction industry has 'room' for third player of scale: experts The slow demise or temporary slump of New Zealand's oil and gas industry Retirement village investment in its infancy but demand's set to grow Government wants Free Trade Agreements to cover 90 per cent of exports David Walsh named new chief executive of NZ Post Construction of cellphone tower on footpath sparks controversy Vodafone and Spark in takeover tussle over TeamTalk How Toyota poured 500 years of work into its new campus - during a labour shortage Chart of the day: How many Northland students are at or above National Standards? Oil and gas industry says plenty of water under bridge before oil drills hit Lake Te Anau

Fisher & Paykel Healthcare has raised its earnings guidance and brought forward plans to expand its manufacturing facility in Mexico.

The firm's annual profit for the year to March 31 is now seen at $97 million, up from the November forecast of $90-$95m.

"Demand during the second half has been very encouraging, particularly for our Simplus, Eson and Pilairo Q masks, which are used for the treatment of OSA,'' chief executive Michael Daniell said.

''Operating margin has continued to improve as a result of product mix, operating efficiency gains and manufacturing at our Mexico facility".

The company said it will expand its plant in Tijuana, Mexico, spending $4m on a fit-out to increase the manufacturing area by two thirds.

The plant is expected to be manufacturing approximately half of the company's consumable product volume within three years, F & P Healthcare said.

"We have brought forward the expansion of the Tijuana facility to ensure that we can meet anticipated demand as a result of strong customer acceptance of products such as our new masks and Optiflow oxygen therapy system,'' Daniell said.

In the United States later this year, Medicare will begin to penalise hospitals for excessive chronic respiratory patient readmissions, he said.

''We believe that this will increase the demand for our products which can help to improve care in the home for patients with chronic respiratory disease."

The company said it will continue to invest at its site in Auckland, where a number of new product platforms and associated manufacturing lines were being developed.

Ad Feedback

- Fairfax Media

Special offers

Featured Promotions

Sponsored Content